

BIOMARIN PHARMACEUTICAL INC

Form 4

March 05, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BAFFI ROBERT

(Last) (First) (Middle)

C/O BIOMARIN
PHARMACEUTICAL INC., 770
LINDARO ST.

(Street)

SAN RAFAEL, CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

3. Date of Earliest Transaction
(Month/Day/Year)
03/03/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
EVP, Technical Operations

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Code			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount				
Common Stock	03/03/2015	03/03/2015	A		10,500	A	\$ 0 ⁽¹⁾	109,700	D
Common Stock	03/05/2015	03/05/2015	M		11,000	A	\$ 17.86	120,700	D
Common Stock	03/05/2015	03/05/2015	M		3,051	A	\$ 14.39	123,751	D
Common Stock	03/05/2015	03/05/2015	S		14,051	D	\$ 116.3683 ⁽²⁾	109,700	D

Common Stock	23,935	I	Shares held by Baffi Family Trust
--------------	--------	---	-----------------------------------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code V (A) (D)		Date Exercisable Expiration Date	Title
Stock Option (right to buy) Common Stock	\$ 108.36	03/03/2015	03/03/2015	A	23,900	09/03/2015 ⁽³⁾ 03/02/2025	Common Stock
Stock Option (right to buy) Common Stock	\$ 17.86	03/05/2015	03/05/2015	M	11,000	06/17/2009 ⁽⁴⁾ 12/16/2018	Common Stock
Stock Option (right to buy) Common Stock	\$ 14.39	03/05/2015	03/05/2015	M	3,051	11/12/2009 ⁽⁶⁾ 05/11/2019	Common Stock

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BAFFI ROBERT
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL, CA 94901

EVP, Technical Operations

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact

03/05/2015

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Restricted stock units granted on March 3, 2015. Price not applicable.

The price in column 4 is a weighted average price. The price actually received ranged from \$116.30 to \$116.44. The reporting person will

(2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

(3) Option grant vests 6/48ths on September 3, 2015, and 1/48th on the 3rd day of every month thereafter.

(4) Option grant vests 6/48ths on June 17, 2009 and 1/48th on the 17th of every month thereafter.

(5) Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.

(6) Option grant vests 6/48ths on November 11, 2009 and 1/48th on the 11th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.